sfa 14:0

SFA 14:0, more commonly known in biochemistry and nutrition as myristic acid, is a long‑chain saturated fatty acid composed of 14 carbon atoms with no double bonds. Chemically referred to as tetradecanoic acid, this fatty acid is a straight‑chain saturated molecule (CH3(CH2)12COOH) that exists as a waxy solid at room temperature. Myristic acid is naturally found in many animal fats and some plant oils, particularly in dairy fats such as butterfat and full‑fat milk, as well as in tropical fats like coconut oil and palm kernel oil. It was originally isolated from nutmeg butter, from which it derives its name (Myristica fragrans). Within cells, myristic acid plays a unique biochemical role beyond basic energy provision: it participates in protein modification processes such as N‑terminal myristoylation, where a myristoyl group is covalently attached to the N‑terminal glycine of certain proteins, enabling those proteins to associate with cellular membranes and influence signaling pathways. This lipidation is essential in the function of various signaling proteins and immune regulators in eukaryotic organisms.

Myristic acid contributes to human metabolism largely in ways shared with other saturated fatty acids, serving as a dense energy source (9 kcal per gram) and partaking in the structural composition of cell membranes. Its biochemical function in protein lipidation, specifically N‑myristoylation, is critical for targeting proteins to membranes and regulating diverse cellular processes including signal transduction and immune responses. However, from a nutrition and health perspective, myristic acid is best known for its influence on plasma cholesterol. It is among the most potent of dietary saturated fatty acids in raising both low‑density lipoprotein (LDL) and high‑density lipoprotein (HDL) cholesterol when compared with unsaturated fats, with implications for atherogenic risk when consumed in high amounts. Public health organizations like the American Heart Association emphasize that saturated fats, including myristic acid, can adversely affect lipid profiles and should be replaced with unsaturated fats to lower cardiovascular disease risk. Evidence from systematic reviews indicates that dietary patterns high in saturated fats are associated with increased total and LDL cholesterol, a well‑established risk factor for coronary heart disease. The mechanisms include downregulation of LDL receptor activity and alterations in lipid transport particles. Additionally, newer research suggests that diets lower in specific saturated fatty acids (C12:0 and C14:0) can yield more favorable plasma lipid profiles compared to diets merely reducing other saturated fats. While individual saturated fatty acids may vary in their impact, the overall health benefit from limiting their intake and replacing them with polyunsaturated fats is supported by clinical and guideline evidence.

Unlike essential fatty acids such as omega‑3 or omega‑6 fatty acids, myristic acid does not have a required intake level established by nutritional authorities because the human body can produce sufficient quantities from other substrates, and there is no deficiency condition directly linked to lack of intake. Dietary reference intakes set by the National Academies and U.S. guidelines do not specify RDAs for individual saturated fatty acids but instead address macronutrient distribution ranges that include limits for total saturated fats. Current recommendations from the Dietary Guidelines for Americans suggest that saturated fat intake should account for less than 10% of total daily calories to support cardiovascular health, with some organizations recommending even lower thresholds (e.g., <6% for those at high CVD risk). These guidelines imply that intake of myristic acid, as part of overall saturated fats, should be limited rather than optimized for a specific amount. In practical dietary planning, attention is focused on the types of fats consumed: emphasizing mono‑ and polyunsaturated fats from plant oils, nuts, seeds, and fatty fish while reducing intake of saturated fat‑rich foods including high‑fat dairy and certain tropical oils.

Because myristic acid is not considered essential, there are no deficiency diseases attributed to inadequate intake. The body is capable of synthesizing saturated fatty acids via de novo lipogenesis from carbohydrate and other substrates, ensuring baseline physiological needs are met. Therefore, specific clinical signs tied to myristic acid deficiency are not recognized in medical practice. Instead, nutritional concern centers on excess intake and its impact on lipid metabolism and disease risk. Individuals with very low fat diets may experience general signs of inadequate dietary fat such as poor absorption of fat‑soluble vitamins (A, D, E, K) and compromised energy intake, but these are not specific to myristic acid. Accordingly, deficiency content focuses on general fat inadequacy rather than a myristic acid‑specific condition.

Myristic acid appears predominantly in foods rich in saturated fat. The highest concentrations are found in certain plant fats like coconut oil and palm kernel oil, as well as animal fats from dairy products. Foods ranked by myristic acid content include coconut milk, shredded dried coconut, and light whipped cream, along with various cheeses. Dairy items such as parmesan, ricotta, and whole milk contribute moderate amounts of myristic acid per serving. Tropical oils such as coconut and palm kernel oils contain the highest concentrations among edible fats, often with more than 15 grams per 100 grams of oil. Meat and fish also provide myristic acid, albeit at lower concentrations; examples include cooked herring, lamb shortribs, and cooked mackerel. Food processing and culinary preparation can also influence levels: butter oil and anhydrous dairy fats are particularly dense sources. While sweets and confectionery items may contain myristic acid due to added dairy and coconut ingredients, these sources also contribute added sugars and calories. It is important to balance the enjoyment of these foods with overall dietary patterns, given the lipid effects associated with saturated fats.

As a long‑chain saturated fatty acid, myristic acid undergoes digestion and absorption similar to other fats. Dietary triglycerides containing myristic acid are emulsified by bile salts in the small intestine and hydrolyzed by pancreatic lipases, resulting in free fatty acids and monoglycerides that are absorbed by enterocytes. Within enterocytes, fatty acids are re‑esterified into triglycerides and incorporated into chylomicrons for transport via lymphatic circulation to the bloodstream. Factors that enhance absorption include the presence of bile acids and efficient pancreatic enzyme activity. Conversely, conditions that impair fat digestion—such as cholestatic liver disease, pancreatic insufficiency, or bile acid malabsorption—can reduce uptake of myristic acid and other long‑chain fats. Dietary components like soluble fiber and plant sterols may modestly inhibit absorption by binding bile acids or altering micelle formation. Unlike medium‑chain triglycerides, which are absorbed more directly into the portal circulation, myristic acid follows the longer chylomicron‑dependent pathway typical of long‑chain fatty acids.

Supplementation with myristic acid itself is not recommended and there are no established therapeutic doses. Unlike essential nutrients where supplements may correct a deficiency or optimize levels, myristic acid does not have a deficiency syndrome, and its dietary contribution is usually covered in normal eating patterns that include fats. On the contrary, excessive intake of saturated fats—including myristic acid—may negatively impact lipid profiles, particularly LDL cholesterol. Public health guidance suggests reducing intake of foods rich in myristic acid and other saturated fats rather than supplementing them. If individuals are considering supplements for general fat intake, emphasis should be on essential fatty acids like omega‑3 (EPA, DHA, ALA) or omega‑6 fats rather than saturated fats. Professional advice from a dietitian or healthcare provider can guide personalized decisions based on overall dietary patterns and health status.

There is no specific tolerable upper intake level established for myristic acid itself. Toxicity in the classical sense does not occur because the body metabolizes saturated fatty acids routinely as part of energy homeostasis. However, high intake of myristic acid as part of a diet high in saturated fats can significantly raise low‑density lipoprotein cholesterol, a risk factor for atherosclerotic cardiovascular disease. National dietary guidelines recommend limiting saturated fats to less than 10% of total energy intake to reduce this risk. Some organizations recommend even lower percentages for those with high cardiovascular risk. Chronic high saturated fat intake can contribute to lipid imbalances, adiposity, insulin resistance, and inflammation. Monitoring dietary patterns with a focus on fat quality rather than specific fatty acid toxicity is more relevant in clinical nutrition than looking at myristic acid alone.

There are no specific medications known to interact directly with myristic acid itself. However, because myristic acid influences lipid metabolism and can raise LDL cholesterol, it may have implications for lipid‑lowering therapies such as statins or bile acid sequestrants. These medications aim to reduce LDL levels, and high saturated fat intake may counteract therapeutic goals. Individuals taking cholesterol‑lowering drugs may benefit from limiting dietary sources of myristic acid and other saturated fats to optimize treatment efficacy. Additionally, conditions affecting fat digestion—such as use of orlistat or other lipase inhibitors—can reduce absorption of long‑chain fatty acids including myristic acid.

⚠️ Interactions: May influence LDL levels affecting lipid‑lowering drugs